Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Keros Therapeutics (KROS) Return on Sales (2019 - 2025)

Keros Therapeutics' Return on Sales history spans 7 years, with the latest figure at 40.66% for Q4 2025.

  • For Q4 2025, Return on Sales fell 13126.0% year-over-year to 40.66%; the TTM value through Dec 2025 reached 0.36%, down 156092.0%, while the annual FY2025 figure was 0.36%, N/A changed from the prior year.
  • Return on Sales reached 40.66% in Q4 2025 per KROS's latest filing, down from 0.51% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 15885.0% in Q1 2021 to a low of 5410.0% in Q3 2023.
  • Average Return on Sales over 5 years is 384.98%, with a median of 4.05% recorded in 2022.
  • Peak YoY movement for Return on Sales: surged 1588781bps in 2021, then crashed -1588634bps in 2022.
  • A 5-year view of Return on Sales shows it stood at 0.39% in 2021, then crashed by -1400bps to 5.82% in 2022, then tumbled by -5486bps to 324.86% in 2023, then skyrocketed by 128bps to 90.6% in 2024, then crashed by -145bps to 40.66% in 2025.
  • Per Business Quant, the three most recent readings for KROS's Return on Sales are 40.66% (Q4 2025), 0.51% (Q3 2025), and 1.69% (Q2 2025).